This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

American Pacific's CEO Discusses F3Q12 Results - Earnings Call Transcript

Because of this outlook we are increasing guidance for our continuing operations, we are providing guidance of $36 million in EBITDA in fiscal 2012, a 26% increase over 2011 based on continuing operations for both years. Dana will discuss guidance in more detail later in this conference call.

Let us now discuss each of the business segments beginning with our fine chemical segment. The fine chemical team exceeded our expectations for the third quarter, client utilization and throughput has improved resulting in improved profit margins. Also our cost reduction initiative especially in the area of solvent recycling has contributed to the bottom-line performance.

The increase in plant utilization is been driven by our major core products, our two large simulated moving bed or SMB units are being fully utilized. You may be called and reported last quarter that we entered into a new 5 year agreement for the central nervous system product that utilizes our large SMB units.

Despite this product now been off pattern, our customer continues to retain significant market share with AMPAC buying chemicals being the primary supplier of the active pharmaceutical ingredient. Our anti-viral products are also driving the increase in plant utilization as well as achieving targeted throughput. Our development product pipeline continues to bear fruit enabling us to bring new products to the market. We have successfully completed the validation of two new cancer drugs and are currently producing them at commercial scale, both of use novel mechanisms to treat different types of cancer.

In addition, we anticipate bringing a third new product to market. We are currently validating the process for the production of our first controlled substance. This is a major accomplishment that will lead to continue new opportunities for our fine chemical segment. This area of controlled substances has significant barriers to entry and we are pleased to have been able to penetrate those barriers and be one of the few U.S. producers of pharmaceutical chemicals in this arena.

Read the rest of this transcript for free on

3 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free


Chart of I:DJI
DOW 16,776.43 +304.06 1.85%
S&P 500 1,987.05 +35.69 1.83%
NASDAQ 4,781.2640 +73.4890 1.56%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs